Zhang ZN, Hao L, Han S, Li SS, Lin SX, Miao YD. Harnessing the prognostic power of preoperative systemic immune-inflammation index/albumin ratio in hepatocellular carcinoma resection. World J Gastrointest Surg 2025; 17(2): 102261 [DOI: 10.4240/wjgs.v17.i2.102261]
Corresponding Author of This Article
Yan-Dong Miao, Cancer Center, Yantai Affiliated Hospital of Binzhou Medical University, The 2nd Medical College of Binzhou Medical University, No. 717 Jinbu Street, Muping District, Yantai 264100, Shandong Province, China. miaoyd_22@bzmc.edu.cn
Research Domain of This Article
Oncology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Zhao-Nan Zhang, Liang Hao, Shuang Han, Shan-Shan Li, Si-Xiang Lin, Yan-Dong Miao, Cancer Center, Yantai Affiliated Hospital of Binzhou Medical University, The 2nd Medical College of Binzhou Medical University, Yantai 264100, Shandong Province, China
Co-first authors: Zhao-Nan Zhang and Liang Hao.
Co-corresponding authors: Si-Xiang Lin and Yan-Dong Miao.
Author contributions: Zhang ZN and Hao L performed the literature retrieval and wrote the manuscript, contributed equally to this work; Han S and Li SS performed the data analysis; Lin SX was responsible for the evolution of overarching research goals and aims, specifically critical review, management and coordination responsibility for the research activity planning and execution, while Miao YD was responsible for review and editing the draft, oversight, and leadership responsibility for the research activity planning and execution, including mentorship external to the core team, acquisition of the financial support for the project leading to this publication. All authors approved the final manuscript.
Supported by Shandong Province Medical and Health Science and Technology Development Plan Project, No. 202203030713; and Science and Technology Program of Yantai Affiliated Hospital of Binzhou Medical University, No. YTFY2022KYQD06.
Conflict-of-interest statement: No conflict of interest associated with any of the senior authors or other coauthors contributed their efforts to this manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yan-Dong Miao, Cancer Center, Yantai Affiliated Hospital of Binzhou Medical University, The 2nd Medical College of Binzhou Medical University, No. 717 Jinbu Street, Muping District, Yantai 264100, Shandong Province, China. miaoyd_22@bzmc.edu.cn
Received: October 13, 2024 Revised: December 5, 2024 Accepted: December 16, 2024 Published online: February 27, 2025 Processing time: 100 Days and 22.4 Hours
Core Tip
Core Tip: The study highlights the significance of the preoperative systemic immune-inflammation index/albumin (SII/ALB) ratio as an independent prognostic indicator for hepatocellular carcinoma patients undergoing curative resection. The SII/ALB ratio integrates inflammatory and nutritional biomarkers, providing a cost-effective and accessible tool for predicting overall and recurrence-free survival. Additionally, a predictive nomogram incorporating SII/ALB with clinical parameters improves patient stratification, guiding surgical decisions and postoperative care. While promising, further multi-center validation across diverse patient populations is needed to confirm its broad clinical applicability. Moreover, dynamic monitoring of SII/ALB throughout treatment could enhance personalized therapy, making it a valuable asset even in resource-limited healthcare settings.
